{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:13:45Z","timestamp":1792030425061,"version":"4.4.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.japh.2019.09.001","type":"journal-article","created":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T17:56:53Z","timestamp":1570816613000},"page":"31-38.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Real-world impact on monthly glucose-lowering medication cost, HbA1c, weight, and polytherapy after initiating a GLP-1 receptor agonist"],"prefix":"10.1016","volume":"60","author":[{"given":"Tayla N.","family":"Rose","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle L.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra J.","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla J.","family":"Bouwmeester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Conley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borna","family":"Fatehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Matta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith T.","family":"Barr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.japh.2019.09.001_bib1","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1345\/aph.1D479","article-title":"Development and validation of the medication regimen complexity index","volume":"38","author":"George","year":"2004","journal-title":"Ann Pharmacother"},{"issue":"2","key":"10.1016\/j.japh.2019.09.001_bib2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/1060028016673652","article-title":"Medication regimen complexity and A1C goal attainment in underserved adults with type 2 diabetes","volume":"51","author":"Yeh","year":"2017","journal-title":"Ann Pharmacother"},{"issue":"5","key":"10.1016\/j.japh.2019.09.001_bib3","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2337\/dci18-0007","article-title":"Economic costs of diabetes in the U.S. in 2017","volume":"41","year":"2018","journal-title":"Diabetes Care"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.japh.2019.09.001_bib4","first-page":"S1","article-title":"Standards of medical care in diabetes\u20142019","volume":"42","year":"2019","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.japh.2019.09.001_bib6","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1463-1326.2010.01327.x","article-title":"Patient perspectives on once-weekly medications for diabetes","volume":"13","author":"Polonsky","year":"2011","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.japh.2019.09.001_bib7","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12955-017-0696-7","article-title":"Evaluation of the impact of once weekly dulaglutide on patient-reported outcomes in Japanese patients with type 2 diabetes: comparisons with liraglutide, insulin glargine, and placebo in two randomized studies","volume":"15","author":"Suzuki","year":"2017","journal-title":"Health Qual Life Outcomes"},{"issue":"7","key":"10.1016\/j.japh.2019.09.001_bib8","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/dom.12902","article-title":"Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon-like peptide-1 receptor agonists: higher adherence and persistence with dulaglutide compared with once-weekly exenatide and liraglutide","volume":"19","author":"Alatorre","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.japh.2019.09.001_bib9","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s13300-018-0396-2","article-title":"Utilization patterns of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus in Italy: a retrospective cohort study","volume":"9","author":"Federici","year":"2018","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.japh.2019.09.001_bib10","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2147\/PPA.S151736","article-title":"Adherence to antihyperglycemic medications and glucagon-like peptide 1-receptor agonists in type 2 diabetes: clinical consequences and strategies for improvement","volume":"12","author":"Giorgino","year":"2018","journal-title":"Patient Prefer Adherence"},{"issue":"3","key":"10.1016\/j.japh.2019.09.001_bib11","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1007\/s12325-016-0470-y","article-title":"Glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy adherence for patients with type 2 diabetes in a Medicare population","volume":"34","author":"Nguyen","year":"2017","journal-title":"Adv Ther"},{"issue":"9683","key":"10.1016\/j.japh.2019.09.001_bib12","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","article-title":"Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)","volume":"374","author":"Buse","year":"2009","journal-title":"Lancet"},{"issue":"9662","key":"10.1016\/j.japh.2019.09.001_bib13","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(08)61246-5","article-title":"Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial","volume":"373","author":"Garber","year":"2009","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.japh.2019.09.001_bib14","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1464-5491.2009.02666.x","article-title":"Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU)","volume":"26","author":"Marre","year":"2009","journal-title":"Diabet Med"},{"issue":"1","key":"10.1016\/j.japh.2019.09.001_bib15","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2337\/dc08-1355","article-title":"Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the lead (liraglutide effect and action in diabetes)-2 study","volume":"32","author":"Nauck","year":"2009","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.japh.2019.09.001_bib16","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1007\/s00125-009-1472-y","article-title":"Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial","volume":"52","author":"Russell-Jones","year":"2009","journal-title":"Diabetologia"},{"issue":"7","key":"10.1016\/j.japh.2019.09.001_bib17","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.2337\/dc08-2124","article-title":"Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD)","volume":"32","author":"Zinman","year":"2009","journal-title":"Diabetes Care"},{"issue":"9951","key":"10.1016\/j.japh.2019.09.001_bib18","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/S0140-6736(14)60976-4","article-title":"Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial","volume":"384","author":"Dungan","year":"2014","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.japh.2019.09.001_bib19","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.2337\/dc14-1625","article-title":"Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2)","volume":"38","author":"Giorgino","year":"2015","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.japh.2019.09.001_bib20","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S2213-8587(18)30023-8","article-title":"Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial","volume":"6","author":"Ludvik","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"10.1016\/j.japh.2019.09.001_bib21","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.2337\/dc13-2760","article-title":"Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1)","volume":"37","author":"Wysham","year":"2014","journal-title":"Diabetes Care"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.japh.2019.09.001_bib22","doi-asserted-by":"crossref","first-page":"124","DOI":"10.2337\/db18-124-OR","article-title":"Comparing treatment strategies for patients with very elevated HbA1c\u2014a randomized trial","volume":"67","author":"Abreu","year":"2018","journal-title":"Diabetes. [abstract]"},{"issue":"12","key":"10.1016\/j.japh.2019.09.001_bib23","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.2337\/dci18-0033","article-title":"Management of hyperglycemia in type 2 diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.japh.2019.09.001_bib24","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s13300-016-0219-2","article-title":"Evaluating the long-term cost-effectiveness of daily administered GLP-1 receptor agonists for the treatment of type 2 diabetes in the United Kingdom","volume":"8","author":"Hunt","year":"2017","journal-title":"Diabetes Ther"},{"issue":"6","key":"10.1016\/j.japh.2019.09.001_bib25","first-page":"1039","article-title":"Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis","volume":"15","author":"Pelletier","year":"2012","journal-title":"J\u00a0Med Econ"},{"issue":"2","key":"10.1016\/j.japh.2019.09.001_bib26","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s13300-014-0080-0","article-title":"Cost-utility analysis of glucagon-like peptide-1 agonists compared with dipeptidyl peptidase-4 inhibitors or neutral protamine Hagedorn basal insulin as add-on to metformin in type 2 diabetes in Sweden","volume":"5","author":"Kiadaliri","year":"2014","journal-title":"Diabetes Ther"},{"issue":"3","key":"10.1016\/j.japh.2019.09.001_bib27","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s13300-017-0250-y","article-title":"Cost-effectiveness of liraglutide versus dapagliflozin for the treatment of patients with type 2 diabetes mellitus in the UK","volume":"8","author":"Vega-Hernandez","year":"2017","journal-title":"Diabetes Ther"},{"issue":"8","key":"10.1016\/j.japh.2019.09.001_bib28","first-page":"573","article-title":"Cost-effectiveness of once daily GLP-1 receptor agonist lixisenatide compared to bolus insulin both in combination with basal insulin for the treatment of patients with type 2 diabetes in Norway","volume":"18","author":"Huetson","year":"2015","journal-title":"J\u00a0Med Econ"},{"issue":"12","key":"10.1016\/j.japh.2019.09.001_bib29","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1007\/s12325-013-0074-8","article-title":"The initiator study: pilot data on real-world clinical and economic outcomes in US patients with Type 2 Diabetes initiating injectable therapy","volume":"30","author":"Thayer","year":"2013","journal-title":"Adv Ther"},{"key":"10.1016\/j.japh.2019.09.001_bib30","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2147\/CEOR.S69981","article-title":"Estimating the real world daily usage and cost for exenatide twice daily and liraglutide in Germany, the Netherlands, and the UK based on volumes dispensed by pharmacies","volume":"7","author":"McDonell","year":"2015","journal-title":"ClinicoEconomics Outcomes Res"},{"issue":"2","key":"10.1016\/j.japh.2019.09.001_bib31","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1001\/jama.285.2.182","article-title":"Effect of improved glycemic control on health care costs and utilization","volume":"285","author":"Wagner","year":"2001","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.japh.2019.09.001_bib32","first-page":"59","article-title":"Association between sustained glycated hemoglobin control and healthcare costs","volume":"5","author":"Juarez","year":"2013","journal-title":"Am J Pharm Benefits"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319119304170?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319119304170?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:46:06Z","timestamp":1761543966000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319119304170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S1544319119304170"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2019.09.001","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world impact on monthly glucose-lowering medication cost, HbA1c, weight, and polytherapy after initiating a GLP-1 receptor agonist","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2019.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}